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Abstract. Interleukin-1β (IL-1β) has a significant role in 
chronic gastric inflammation and manifestations of gastric 
diseases. The present study aimed to elucidate the specific 
role of IL-1β in induction of DNA methylation using IL‑1 
receptor type 1 knockout (IL‑1R1-/-) mice. In the present study, 
wild‑type (WT) and IL‑1R1-/- mice were injected with IL‑1β 
(5 µg/kg/day). Serum levels of IL‑1β, interleukin‑6 (IL‑6) and 
nitric oxide (NO) were measured by enzyme‑linked immuno-
sorbent or NO assays. E‑cadherin (E‑cad) methylation status 
and messenger (m)RNA expression of IL‑1β, IL‑6, E‑cad 
and inducible nitric oxide synthase (iNOS) were analyzed. 
Results from the present study indicated significantly higher 
IL-1β mRNA expression (P<0.001) in WT mice compared 
with IL-1R1-/- mice. IL‑1β and IL‑6 release was significantly 
increased in treated WT mice compared with IL‑1R1-/- mice at 
1 h, 4 h and 8 h (all P<0.005). IL‑1β release was only detected 
in WT mice following a second dose measured at day 3, week 1 
and week 2 when compared with IL‑1R1-/- mice. Promoter 
methylation of E‑cad and a decrease in gene expression was 
observed in treated WT mice. mRNA expression of iNOS 
in WT mice was significantly increased at week 1 compared 
with IL-1R1-/- mice (P=0.0411). Furthermore, a significantly 
increased level of NO production was observed in treated WT 
mice (P<0.005 at 8 h and week 1; P<0.001 at 4 h and day 3) 
when compared with IL‑1R1-/- mice. The present results indi-
cated that IL‑1β was able to directly induce DNA methylation, 
which may link inflammation‑induced epigenetic changes and 
the development of gastric diseases.
Introduction
The inflammatory response is the body's natural response to 
invasion by an infectious agents or tissue damage. However, 
prolonged inflammation may activate cell proliferation and 
induce deregulation of cell death in affected tissues (1). Thus, 
chronic inflammation is now recognized as a predisposing 
cause of many types of cancer, including liver and gastric (2). 
Proinflammatory cytokines, including interleukin‑1β (IL-1β), 
interleukin‑6 (IL‑6) and tumor necrosis factor (TNF‑α), are 
produced by stimulated inflammatory cells and epithelial 
cells during mucosal inflammation (3). IL‑1β is a potent 
inflammatory mediator that has a significant role in initiating 
and amplifying the inflammatory response against Helico‑
bacter pylori infection (4). The present authors and others 
have previously demonstrated that IL‑1β induced by H. pylori 
infection promotes gastric carcinogenesis (5,6). Furthermore, 
the significant role of IL‑1β in increasing the risk of gastric 
inflammation and cancer has been demonstrated by using a 
transgenic model overexpressing human IL‑1β protein (7). 
IL-1β is known to activate the nuclear factor κB (NF‑κB) 
signaling pathway and elicit IL‑6 production (8). IL‑1β induced 
by H. pylori infection led to upregulation of inducible nitric 
oxide synthase (iNOS) and overproduction of nitric oxide 
(NO) (9). Accumulating evidence demonstrates that overpro-
duction of NO may induce irreversible mucosal DNA damage, 
which has been proposed to be involved in the initiation and 
promotion of gastric tumor growth (10).
Promoter CpG island methylation is frequently present 
in non‑neoplastic gastric mucosa with H. pylori‑induced 
gastritis (11,12). E‑cadherin (E‑cad) is a tumor‑suppressor 
gene and its promoter hypermethylation has been observed 
to have a significant role in gastric carcinogenesis (11,13,14). 
Therefore, inflammation has been suggested to be an inducer 
of aberrant DNA methylation and a crucial driving force in 
the development of gastric cancer. This is evidenced by the 
frequent detection of E‑cad methylation in non‑neoplastic 
gastric mucosa with H. pylori infection (15).
It has been demonstrated that IL‑1β may induce DNA 
methylation in vitro (16‑18). This methylation‑dependent 
gene silencing mechanism is via IL‑1β activation of NO 
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production (16,18). Thus, the present study used mice in which 
the interleukin 1 receptor type 1 (IL‑1R1) was deleted in order 
to characterize the specific role of IL‑1β in H. pylori‑induced 
DNA methylation. Previously the present authors demonstrated 
that H. pylori infection induced severe gastritis with enhanced 
IL-1β production is likely a prerequisite mechanism for DNA 
methylation (5). However, whether H. pylori‑induced DNA 
methylation is IL‑1β‑dependent, or whether this phenomenon 
is the result of a complex interaction due to the host immune 
response to H. pylori infection, irrespective of IL‑1β, remains 
to be elucidated.
The present study aimed to elucidate the biological 
activity of IL‑1β in the initiation of gastric inflammation, and 
additionally investigated the specific role of IL‑1β in linking 
inflammation with DNA methylation by using IL‑1R1‑homo-
zygous‑knockout (IL‑1R1-/-) mice.
Materials and methods
Animals. IL-1R1-/- mice from a C57BL/6 background were 
purchased from the Jackson Laboratory (Bar Harbor, ME, 
USA). The IL‑1R1-/- mice and their C57BL/6 wild‑type 
cohorts (WT) were bred and housed in the Animal Unit at 
the University of Hong Kong (Hong Kong, China). The mice 
were kept in individually ventilated cages (Tecniplast, West 
Chester, PA, USA) in an air‑conditioned room at 23±1˚C with 
a 12/12 h light/dark cycle with access ad libitum to water 
and food (Ralston Purina Co., Chicago, IL, USA). Male WT 
and IL‑1R1-/- mice (4‑6 weeks old), weighing 20‑25 g were 
randomly split into groups (n=4‑8 for each time point). All 
experimental protocols were approved by the Hong Kong 
Department of Health and the Committee on the Use of Live 
Animals for Teaching and Research of The University of Hong 
Kong (Hong Kong, China; approval no., 1327‑06).
Intraperitoneal challenges. To elucidate the role of IL‑1β in 
induction of DNA methylation in vivo, WT and IL‑1R1-/- mice 
(n=8 in each group) were treated with intraperitoneal injec-
tion of recombinant mouse IL‑1β (5 µg/kg/day; R&D Systems, 
Inc., Minneapolis, MN, USA) on day 0 and day 2. Controls for 
the two strains (n=4) were treated with an identical volume 
of phosphate‑buffered saline (PBS; Invitrogen; Thermo Fisher 
Scientific, Inc., Waltham, MA, USA) solution. The dose of 
IL-1β was selected based on dose response studies to induce 
an inflammatory response (19) and preliminary experiments 
where it was observed that 5 µg/kg/day of IL-1β caused 
measurable effects.
Preparation of specimens. Mice were sacrificed using anes-
thesia at 1 day, 3 days, 1 week and 2 weeks subsequent to 
injection. Blood was taken from the tail vein 0, 1, 4 and 8 h 
following IL-1β injection and subsequent to sacrifice to inves-
tigate the serum levels of IL‑1β, IL‑6 and NO. The stomach 
was resected and snap‑frozen for additional analysis.
Measurement of cytokines. The blood levels of proinflam-
matory cytokines IL‑1β and IL‑6 were determined using the 
mouse IL‑1β and IL‑6 Quantikine® Colorimetric Sandwich 
enzyme‑linked immunosorbent assay (ELISA) (R&D Systems, 
Inc.) according to the manufacturer's protocol. Absorbance 
was measured at 450 nm by a microplate reader (µQaunt™ 
Microplate Spectrophotometer; Bio‑Tek Instruments, Inc., 
Winooski, VT, USA). Each measurement was repeated in 
triplicate, and the mean value was recorded (in pg/ml).
Methylation analysis. Genomic DNA was extracted from 
frozen mucosa specimens using the DNeasy Blood & Tissue 
kit (Qiagen GmbH, Hilden, Germany). The promoter meth-
ylation status of E‑cad was assessed by restriction enzyme 
digestion followed by polymerase chain reaction (PCR) as 
previously described (20). Briefly, 500 ng of genomic DNA 
was digested with restriction enzymes HpaII (40 units/ml) and 
MspI (50 units/ml; both Invitrogen; Thermo Fisher Scientific) 
at 37˚C overnight in a total volume of 20 µl. HpaII and MspI 
cut DNA at the CCGG sequence; however, HpaII does not cut 
when the internal cytosine is methylated. A parallel assay using 
heat inactivated MspI was performed for each DNA sample 
as the negative control (20). DNA samples extracted from 
the mouse tail was methylated in vitro with CpG methylase 
(M.SssI; Zymo Research, Irvine, CA, USA) was used as a posi-
tive control. Following digestion, 1 µl of each digest underwent 
PCR amplification. The PCR reaction was performed using 
AmpliTaq Gold® DNA Polymerase (Invitrogen; Thermo Fisher 
Scientific, Inc.) at 95˚C for 2 min, followed by 35 cycles of 
denaturation at 94˚C for 45 s, annealing at 57˚C for 45 sec and 
elongation at 72˚C for 45 sec, followed by a final extension 
step of 5 min at 72˚C. The PCR amplification was performed 
using the GeneAmp® 9700 PCR System (Applied Biosystems®; 
Thermo Fisher Scientific, Inc.). PCR products and a 50 bp 
DNA ladder (Invitrogen; Thermo Fisher Scientific, Inc.) were 
subjected to electrophoresis on a 2% agarose gel, stained with 
ethidium bromide (Invitrogen; Thermo Fisher Scientific, Inc.) 
and visualized using the Gel Doc XR System (Bio‑Rad Labo-
ratories, Inc., Hercules, CA, USA). Methylation‑positive PCR 
fragments were purified and confirmed by sequencing using 
the TA‑cloning method (Invitrogen; Thermo Fisher Scientific, 
Inc.) as previously described (21). This experiment was repeated 
in triplicate. Gene‑specific PCR primers are listed in Table I 
(synthesised by Invitrogen; Thermo Fisher Scientific, Inc.).
Reverse transcription (RT)‑quantitative (q)PCR analysis of 
gene expression. Total RNA was extracted from snap‑frozen 
mucosa specimens using TRIzol® reagent (Invitrogen; Thermo 
Fisher Scientific, Inc.) according to the manufacturer's protocol. 
Total RNA (2 µg) was reverse transcribed using SuperScript® 
First‑Strand Synthesis system (Invitrogen; Thermo Fisher 
Scientific, Inc.) at 65°C for 10 min, followed by 50˚C for 
30 min and 85˚C for 5 min using the Opticon 2 Real‑Time 
PCR system (Bio‑Rad Laboratories, Inc.). A control reaction 
without reverse transcriptase was included to identify any 
DNA contamination in the samples. RT‑qPCR amplification of 
IL-1β, IL‑6, E‑cad and iNOS was performed in the Opticon 2 
Real‑Time PCR system (Bio‑Rad Laboratories, Inc.) using 
SYBR Green (Bio‑Rad Laboratories, Inc.). Gene expression 
levels were normalized using glyceraldehyde‑3‑phosphate 
dehydrogenase as an internal control gene, and compared 
with the data of untreated mice using the ∆∆Cq method (22). 
The experiment was repeated in three times. Gene‑specific 
PCR primers are listed in Table I (synthesised by Invitrogen; 
Thermo Fisher Scientific, Inc.).
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Nitric oxide assay. Production of NO in mouse serum was 
measured as nitrate, a more stable end product of NO, based 
on the Griess reaction method (23) using a Total Nitric Oxide 
Assay kit (Enzo Life Sciences, Inc., Farmingdale, NY, USA). 
The optical density was measured at 550 nm using a microplate 
reader (µQaunt Microplate Spectrophotometer). All standards 
and samples were measured in triplicate.
Measurement of total DNA methyltransferase (DNMT) 
activity. Nuclear protein extract was obtained from the 
frozen gastric mucosa samples according to the manufac-
turer's protocol using the EpiQuikTM Nuclear Extraction kit 
(Epigentek, Farmingdale, NY, USA). Protein concentrations 
were determined using the Bradford method (Bio‑Rad Labo-
ratories, Inc.) (24). The total DNMT activity was measured 
using the EpiQuikTM DNA methyltransferase activity assay kit 
(Epigentek). Absorbance was determined using a microplate 
spectrophotometer (µQaunt Microplate Spectrophotometer) 
at 450 nm, and DNMT activity (OD/h/mg) was calculated 
according to the manufacturer's protocol.
Statistical analysis. All data are expressed as the mean ± standard 
error. The statistical significance between the two experimental 
groups was analyzed using the student's t‑test. All statistical 
analysis was performed using GraphPad Prism version 5.0 
(GraphPad Software, Inc., La Jolla, CA, USA). P<0.05 was 
considered to indicate a statistically significant difference.
Results
Effect of IL‑1β on induction of inflammatory cytokines. To 
investigate the impact of peripheral IL‑1β challenge on serum 
levels of IL‑1β and IL‑6, ELISAs were performed on blood 
collected at 0, 1, 4 and 8 h subsequent to IL‑1β injection, and 
1 day, 3 days, 1 week and 2 weeks following sacrifice. Control 
mice injected with PBS solution demonstrated an undetectable 
serum level of IL‑1β and IL‑6 at all the time points. As shown 
in Fig. 1A, the IL‑1β level increased significantly between 1 h 
and 8 h post‑injection in wild‑type (WT) mice (23±2.6 pg/ml 
at 1 h, 133±4.8 pg/ml at 4 h, 74±5.2 pg/ml at 8 h; all P<0.005) 
when compared with IL‑1R1-/- mice. Following a peak at 4 h, 
the levels of IL‑1β progressively decreased to an undetectable 
level at 1‑day post‑injection in WT mice. In IL‑1R1-/- mice, 
a low level of IL‑1β was observed only at 1 h post‑injection 
(9.3±1.4 pg/ml), and the IL‑1β level became undetectable 
even following a second dose of IL‑1β on day 2. By contrast, 
in WT mice, following a second dose of IL‑1β, serum levels 
of IL-1β remained detectable at 3 days, 1 week and 2 weeks 
post‑injection (30±2.3 pg/ml, 18±1.2 pg/ml and 13±2.3 pg/ml, 
respectively; all P<0.05) when compared with IL‑1R1-/- mice.
Table I. Primer sequences (5' to 3') used for methylation‑specific PCR and RT‑PCR analysis.





Inducible nitric oxide synthasea CAGCTGGGCTGTACAAACCTT CATTGGAAGTGAAGCGTTTCG
Glyceraldehyde‑3‑Phosphate Dehydrogenasea GACATCAAGAAGGTGGTGAAGC GTCCACCACCCTGTTGCTGTAG 
aprimers for RT‑PCR analysis. bprimers for methylation analysis. PCR, polymerase chain reaction; RT, reverse transcription.
Figure 1. Effect of peripheral IL‑1β challenge on serum levels of (A) IL‑1β and (B) IL‑6 in WT and IL‑1R1-/- mice. Mice were injected with IL‑1β (5 µg/kg/day) 
on day 0 and day 2 (indicated by arrows). Blood was collected and measured by enzyme‑linked immunosorbent assay at 0, 1, 4, 8 h subsequent to IL‑1β injec-
tion, and after sacrifice at 1 day, 3 days, 1 week and 2 weeks. Data are presented as the mean ± standard error. Significant differences are shown by *P<0.05, 
**P<0.005, ***P<0.0005 vs. control mice without injection. IL, interleukin; WT, wild‑type; IL‑1R1, interleukin 1 receptor type 1.
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The serum level of IL‑6 was assessed to confirm that the 
induced IL‑1β was due to peripheral inflammatory cytokine 
IL-1β challenge and not injection. IL‑6 levels increased 
significantly at 1 h post‑injection and reached a peak at 4 h, 
and subsequently became undetectable at 1‑day post‑injection 
(237±11.5 pg/ml at 1 h, 750±24.7 pg/ml at 4 h, 430±5.6 pg/ml at 
8 h; all P<0.0005) in WT mice when compared with IL‑1R1-/- 
mice (Fig. 1B). Unlike IL‑1β, the IL‑6 level was not detectable 
at day 3, 1 week or 2 weeks, even following a second dose of 
IL-1β on day 2. In injected IL‑1R1-/- mice and control mice 
treated with PBS solution, no IL‑6 induction was observed, 
and the IL‑6 level was undetectable at all the time points 
analyzed (Fig. 1B).
Induction of promoter methylation of E‑cad by IL‑1β injec‑
tion. The promoter methylation status of E‑cad was assessed 
in mice gastric mucosae collected at 1 day, 3 days, 1 week and 
2 weeks post‑injection of IL‑1β. Methylation of E‑cad was 
absent in the injected WT and IL‑1R1-/- mice (n=8 in each 
group) at 1‑day post‑injection. Following a second dose of 
IL-1β on day 2, promoter methylation of E‑cad was observed 
in 3/8 (37.5%) WT mice at the 3 day and 1 week time points, 
and 1/8 (12.5%) WT mice at 2‑weeks post‑injection (Fig. 2). 
However, methylation of E‑cad was not detected in IL‑1R1-/- 
mice (n=8) and PBS‑treated control mice (n=4) at all time 
points.
Effect of IL‑1β treatment on mRNA expression of proinflam‑
matory genes, E‑cad and iNOS. A significant change in 
IL-1β messenger (m)RNA expression in the gastric mucosa 
was observed on day 3 in treated WT mice when compared 
with IL-1R1-/- mice or controls treated with PBS (all P<0.001). 
Otherwise, the mRNA expression was comparable between 
treated WT and IL‑1R1-/- mice or controls at all other time 
points measured (data not shown). IL‑1β treatment did not 
induce a statistically significant difference in mRNA expres-
sion of IL‑6 in WT and IL‑1R1-/- mouse gastric mucosae, and 
expression of IL‑6 was almost undetectable in the control 
group (data not shown). A slight decrease in the mRNA 
expression of E‑cad was observed between the IL‑1β‑treated 
WT and IL‑1R1-/- mice, as well as in the control mice treated 
with PBS solution (Fig. 3A). However, IL‑1β treatment 
induced a higher expression of iNOS in WT mice when 
compared with IL‑1R1-/- mice. The expression of iNOS was 
comparable between treated WT mice and IL‑1R1-/- mice on 
day 3 (P=0.058). A statistically significant difference in iNOS 
expression was observed at 1‑week post‑infection in WT mice 
(P=0.0411; Fig. 3B).
Effect of IL‑1β treatment on NO production. The serum NO 
levels obtained in the various groups of mice at different 
time points are illustrated in Fig. 4. The serum level of NO 
was significantly increased in IL‑1β‑injected WT mice when 
compared with IL‑1R1-/- mice at 4 h (195.33±22.33 µM; 
P<0.001), 8 h (138.34±16.24 µM; P<0.005), 3 days 
(182.60±32.2 µM; P<0.001) and 1 week (127.34±12.14 µM; 
P<0.005), respectively. IL‑1β injection did not affect the NO 
level in IL‑1R1-/- mice; the nitrate concentrations measured 
at all three time points were comparable to the basal physi-
ological levels measured in the control mice (Fig. 4).
Figure 2. Promoter methylation analysis of the E‑cad gene in gastric mucosal specimens from WT mice following IL‑1β treatment. (A) Diagrammatic repre-
sentation of the 5' flanking region of the E‑cad gene. Black arrow indicates the location of the primers used for amplification of the E‑cad CpG island. Relative 
positions of the CpG dinucleotides are indicated as vertical lines (not drawn to scale). (B) Sequence of the region of the E‑cad gene analyzed for methylation. 
Primer sequences and restriction site (CCGG) for MspI and HpaII are underlined. (C) Representative gel picture revealing the methylation status of E‑cad in 
WT mouse gastric mucosa. E‑cad methylation was detected in S2 but not in S1 or S3. Positive control demonstrated methylated normal DNA and negative 
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Discussion
Proinflammatory cytokine IL‑1β has a significant role in gastric 
carcinogenesis (16,17,25). In the present study, IL‑1R1-/- mice, 
which are unresponsive to IL‑1β, were used to fully elucidate 
the specific role of IL‑1β in linking gastric inflammation to 
DNA methylation induction. The results indicated that periph-
eral IL-1β challenge may induce proinflammatory cytokine 
release. This is evidenced by the inducible serum IL‑1β and 
IL‑6 in injected WT mice when compared with IL‑1R1-/- mice 
lacking functional receptors to IL‑1β, or control mice without 
IL-1β injection (these mice did not have inducible production 
of serum IL‑1β and IL‑6). These findings were in agreement 
with previous studies that reported that IL‑1β is a significant 
mediator in initiation of the immune response (26,27). The 
present study additionally assayed the serum levels of IL‑6 
to confirm that the increase in IL‑1β was due to induction 
instead of exogenous injection. A previous study additionally 
demonstrated that peripheral challenge of IL‑1β was able to 
induce IL‑6 release (28). However, the serum levels of IL‑6 
were very low and dissipated quickly, suggesting that the 
immune response initiated by IL‑1β treatment may not be a 
potent stimulator for IL‑6 production (28).
The authors of the present study previously demonstrated 
that H. pylori infection induced IL‑1β production and E‑cad 
methylation in in vitro and in vivo experiments. This meth-
ylation induction effect could be reversed following the 
administration of IL‑1β antagonist, interleukin‑1 receptor 
antagonist (5,17,18). These findings suggest the potential mech-
anistic basis of H. pylori in induction of epigenetic changes 
for gastric diseases. In the present study, having demonstrated 
that IL-1β injection was able to initiate an immune response 
evidenced by release of proinflammatory cytokines, the 
methylation status of E‑cad was assessed. Methylation of 
E‑cad was detected in IL‑1β injected WT mice on day 3, 
following a second dose of IL‑1β. This finding was supported 
by a significant upregulation of NO detected on day 3. The 
need for a second dose of IL‑1β may be associated with the 
short half-life of the IL-1β protein, which inadequately elic-
ited a strong immune response following a single dose (29). 
Disappearance of E‑cad methylation was detected 2 weeks 
post‑infection, which was consistent with the plateau of IL‑1β. 
This is additionally in agreement with previous reports that 
severe inflammation is required for initiation and maintenance 
of methylation induction (5,30). Mechanistically, the present 
study observed the absence of E‑cad methylation in IL‑1R1-/- 
mice and controls, suggesting that E‑cad methylation may be 
mediated through an IL‑1β‑dependent signaling pathway. To 
the best of our knowledge, no other study has demonstrated 
that IL-1β injection may induce promoter methylation of E‑cad 
in vivo. Furthermore, the results of the present study suggest 
that inflammatory cytokines may directly trigger epigenetic 
changes.
The results of the present study additionally support the 
mechanism of H. pylori‑induced epigenetic changes and 
gastric carcinogenesis via IL‑1β activation of iNOS and NO 
production, as proposed in our previous studies (5,17,18). 
Excessive NO production causes tissue damage with subse-
quent cellular genome injuries (10). Previous studies have 
demonstrated that NO may activate expression of DNMTs, 
which are the final effector of DNA methylation (16,18,31). 
Figure 3. Expression of (A) E‑cad and (B) iNOS in gastric mucosa of mice challenged with IL‑1β was analyzed by reverse‑transcription quantitative polymerase 
chain reaction 1 day, 3 days, 1 week and 2 weeks post‑injection. The fold increase was calculated at the time point specified relative to internal control genes 
(GAPDH) and compared with control mice without injection at time 0 h. Data are presented as the mean ± standard error. Significant differences are shown by 
*P<0.05 E‑cad, E‑cadherin; iNOS, inducible nitric oxide synthase; IL, interleukin; WT, wild‑type; IL‑1R1, interleukin 1 receptor type 1; mRNA, messenger RNA; 
GAPDH, glyceraldehyde‑3‑phosphate dehydrogenase.
Figure 4. Effect of peripheral IL‑1β challenge on serum levels of NO pro-
duction. WT and IL‑1R1-/- mice were treated with IL‑1β (5 µg/kg/day) on 
day 0 and day 2. NO was measured as nitrate in mouse serum 0, 1, 4 and 8 h 
subsequent to IL‑1β injection, and following sacrifice at 1 day, 3 days, 1 week 
and 2 weeks. Data are presented as the mean ± standard error. Significant 
differences are shown by *P<0.005, **P<0.001 vs. control mice without injec-
tion. IL, interleukin; NO, nitric oxide; WT, wild‑type; IL‑1R1, interleukin 1 
receptor type 1.
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However, no significant changes in total DNMT activity were 
detected in the present study (data not shown). These findings 
are consistent with previous studies, suggesting that mRNA 
expression of DNMTs was not increased in non‑cancerous 
gastric mucosa in humans and mice (5,32). It is likely that 
aberrant DNA methylation results from an imbalance between 
various DNMTs (32‑34). However, the present study provides 
an improved insight into the role of NO in the IL‑1β activated 
methylation‑dependent silencing pathway that may link 
inflammation with gastric carcinogenesis.
Previous studies have reported that IL‑1R1-/- mice demon-
strate attenuated infiltration of inflammatory cells in the stomach 
with H. pylori infection compared with WT mice (5,6). Among 
the infiltrating inflammatory cells in H. pylori‑infected gastric 
mucosa, the IL‑1R1-/- mice demonstrated a significantly reduced 
number of macrophages and neutrophils compared with the WT 
mice. Based on the absence of E‑cad methylation in IL‑1R1-/- 
mice, it may be speculated that IL‑1β directly induces epigenetic 
deregulation and thus promotes gastric carcinogenesis. This is 
supported by the observation that IL‑1R1-/- mice demonstrate 
reduced susceptibility to gastric carcinogenesis (5,6). Although 
significant progress has been made with regard to our under-
standing of the mechanistic link between inflammation and 
gastric cancer development, more comprehensive characteriza-
tion of the role of inflammation in the initiation and maintenance 
of epigenetic changes is required.
In conclusion, the current study demonstrated that IL‑1β may 
directly trigger epigenetic alterations that lead to suppression of 
gene expression. The results provide a significant mechanistic 
link between inflammation and gastric cancer development. 
These findings also highlight the importance of developing treat-
ment strategies that target persistent inflammatory responses to 
achieve the prevention and eradication of disease.
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